A Study of DS3610a in Participants With Advanced Solid Tumor
← catalyst calendarNCT07159126 · readout in 744 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
70estimated
Sites
2
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-09 | actual | When the study began enrolling |
| Primary completion | 2028-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-02-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumors
- Metastatic Solid Tumors
Intervention
- Drug: DS3610a
Primary outcome
what the primary-completion date above is the date OFDose Limiting Toxicities
measured From first dose, up to approximately 24 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed